We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-4.14%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$222M
AUM Growth
+$7.51M
Cap. Flow
+$26.6M
Cap. Flow %
11.96%
Top 10 Hldgs %
87.78%
Holding
26
New
1
Increased
7
Reduced
9
Closed
7

Top Buys

1
QDEL icon
QuidelOrtho
QDEL
+$34.2M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$12.4M
3
APEN
Apollo Endosurgery, Inc.
APEN
+$3.72M
4
EOLS icon
Evolus
EOLS
+$2.12M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$2.12M

Top Sells

1
CSTL icon
Castle Biosciences
CSTL
+$6.48M
2
ADMA icon
ADMA Biologics
ADMA
+$4.8M
3
OVID icon
Ovid Therapeutics
OVID
+$4.07M
4
AFMD
Affimed
AFMD
+$3.24M
5
DMAC icon
DiaMedica Therapeutics
DMAC
+$2.38M

Sector Composition

1 Healthcare 98.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$43.1M 19.37%
6,227,733
-70,615
-1% -$527K
QDEL icon
2
QuidelOrtho
QDEL
$1.19B
$35.9M 16.12%
501,633
+381,846
+319% +$34.2M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$33M 14.83%
5,669,388
+1,988,193
+54% +$12.4M
XERS icon
4
Xeris Biopharma Holdings
XERS
$1.52B
$20.2M 9.07%
12,928,168
+1,280,751
+11% +$2.12M
APEN
5
DELISTED
Apollo Endosurgery, Inc.
APEN
$15.6M 7.02%
2,832,631
+670,632
+31% +$3.72M
ADMA icon
6
ADMA Biologics
ADMA
$2.02B
$12.2M 5.46%
5,000,000
-2,000,000
-29% -$4.8M
URGN icon
7
UroGen Pharma
URGN
$1.96B
$9.35M 4.21%
1,124,220
+13,170
+1% +$109K
AMRN
8
Amarin Corp
AMRN
$292M
$9.32M 4.19%
427,398
-15,290
-3% -$410K
LGND icon
9
Ligand Pharmaceuticals
LGND
$6.08B
$8.57M 3.85%
159,598
-1,093
-0.7% -$64.3K
RZLT icon
10
Rezolute
RZLT
$444M
$8.15M 3.66%
2,973,205
-28,721
-1% -$83K
OPTN
11
DELISTED
OptiNose
OPTN
$7.32M 3.29%
133,333
-41,101
-24% -$2.26M
AFMD
12
DELISTED
Affimed
AFMD
$4.08M 1.83%
197,983
-116,394
-37% -$3.24M
XGN icon
13
Exagen
XGN
$106M
$3.43M 1.54%
1,265,373
+4,986
+0.4% +$27.8K
CFMS
14
DELISTED
Conformis, Inc. Common Stock
CFMS
$3.31M 1.49%
692,174
– –
OVID icon
15
Ovid Therapeutics
OVID
$455M
$2.83M 1.27%
1,540,671
-1,947,257
-56% -$4.07M
ATYR
16
aTyr Pharma
ATYR
$50M
$1.8M 0.81%
600,980
-600
-0.1% -$2.01K
OPNT
17
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$1.64M 0.74%
152,278
– –
EOLS icon
18
Evolus
EOLS
$377M
$1.61M 0.72%
+200,000
New +$2.12M
XOMA
19
DELISTED
Xoma
XOMA
$1.15M 0.52%
64,459
+18,549
+40% +$382K
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.8B
– –
-28,800
Closed -$854K
CDTX
21
DELISTED
Cidara Therapeutics
CDTX
– –
-10,422
Closed -$102K
CSTL icon
22
Castle Biosciences
CSTL
$733M
– –
-295,372
Closed -$6.48M
DMAC icon
23
DiaMedica Therapeutics
DMAC
$393M
– –
-1,176,344
Closed -$2.38M
SYBX
24
DELISTED
Synlogic
SYBX
– –
-6,183
Closed -$107K
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-242,327
Closed -$1.17M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Stonepine Capital Management held 26 positions worth $222M, up 3.5% from $215M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Stonepine Capital Management deployed $26.6M of net new capital in Q3 2022, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Evolus: 200,000 shares worth $1.61M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was ADMA Biologics, an estimated $4.8M trimmed.

  • Stonepine Capital Management's largest Q3 2022 buy was Evolus: 200,000 shares worth $1.61M.
  • Stonepine Capital Management added most to QuidelOrtho in Q3 2022, an estimated $34.2M increase.
  • Stonepine Capital Management's biggest Q3 2022 reduction was ADMA Biologics, cutting an estimated $4.8M.
  • Stonepine Capital Management fully exited Castle Biosciences in Q3 2022, selling an estimated $6.48M.
  • Stonepine Capital Management's ten largest holdings make up 88% of its $222M portfolio in Q3 2022.
  • Stonepine Capital Management opened 1 new position and closed 7 in Q3 2022.
  • Stonepine Capital Management's portfolio value rose 3.5% quarter-over-quarter to $222M.

Based on Stonepine Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.